{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:06:07Z","timestamp":1781211967148,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005629","name":"Takeda Pharmaceuticals America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109449","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T23:07:28Z","timestamp":1778368048000},"page":"109449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient and caregiver priorities of treatment characteristics influencing preferences for tyrosine kinase inhibitors in anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8770-0557","authenticated-orcid":false,"given":"Kenneth W.","family":"Culver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer","family":"Farmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2673-9279","authenticated-orcid":false,"given":"Jaein","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-1933","authenticated-orcid":false,"given":"Jennifer A.","family":"Whitty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Trapali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-4208","authenticated-orcid":false,"given":"Anup","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Danes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109449_b0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","author":"Chia","year":"2014","journal-title":"Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109449_b0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/tlcr-22-656","article-title":"Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review","volume":"12","author":"Chazan","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"issue":"23","key":"10.1016\/j.lungcan.2026.109449_b0015","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.lungcan.2026.109449_b0020","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","article-title":"Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014","volume":"34","author":"Solomon","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109449_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010308","article-title":"EML4-ALK: update on ALK inhibitors","volume":"26","author":"Bearz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2026.109449_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107319","article-title":"Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: systematic review and network meta-analysis","volume":"184","author":"Luo","year":"2023","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109449_b0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/ph13120474","article-title":"The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer","volume":"13","author":"Gristina","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lungcan.2026.109449_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104019","article-title":"From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC","volume":"187","author":"Ou","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lungcan.2026.109449_b0045","doi-asserted-by":"crossref","unstructured":"D.S. Ettinger, D.E. Wood, D.L. Aisner, W. Akerley, J.R. Bauman, A. Bharat, D.S. Bruno, J.Y. Chang, L.R. Chirieac, T.A. D\u2019Amico, M. DeCamp, T.J. Dilling, J. Dowell, S. Gettinger, T.E. Grotz, M.A. Gubens, A. Hegde, R.P. Lackner, M. Lanuti, J. Lin, B.W. Loo, C.M. Lovly, F. Maldonado, E. Massarelli, D. Morgensztern, T. Ng, G.A. Otterson, J.M. Pacheco, S.P. Patel, G.J. Riely, J. Riess, S.E. Schild, T.A. Shapiro, A.P. Singh, J. Stevenson, A. Tam, T. Tanvetyanon, J. Yanagawa, S.C. Yang, E. Yau, K. Gregory, M. Hughes, Non\u2013Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network 20(5) (2022) 497-530.","DOI":"10.6004\/jnccn.2022.0025"},{"key":"10.1016\/j.lungcan.2026.109449_b0050","article-title":"Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: a systematic review of clinical trials","volume":"10781552251387058","author":"Agrawal","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109449_b0055","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins including lorlatinib-resistant compound mutations","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109449_b0060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","article-title":"Natural history and factors associated with overall survival in stage IV ALK-rearranged non\u2013small cell lung cancer","volume":"14","author":"Pacheco","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2026.109449_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194792","article-title":"What is most important to family caregivers when helping patients make treatment-related decisions: findings from a national survey","volume":"15","author":"Bechthold","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109449_b0070","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/hex.13805","article-title":"Family caregiver roles and challenges in assisting patients with cancer treatment decision-making: analysis of data from a national survey","volume":"26","author":"Dionne-Odom","year":"2023","journal-title":"Health Expect."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109449_b0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjsurg.2018.01.011","article-title":"Association of shared decision-making on patient-reported health outcomes and healthcare utilization","volume":"216","author":"Hughes","year":"2018","journal-title":"Am. J. Surg."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109449_b0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40258-013-0023-3","article-title":"Patient preferences versus physicians' judgement: does it make a difference in healthcare decision making?","volume":"11","author":"Muhlbacher","year":"2013","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"7414","key":"10.1016\/j.lungcan.2026.109449_b0085","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/bmj.327.7414.542","article-title":"The importance of patient preferences in treatment decisions\u2013challenges for doctors","volume":"327","author":"Say","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109449_b0090","article-title":"Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States","volume":"211","author":"Le","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109449_b0095","unstructured":"Food and Drug Administration, Incorporating voluntary patient preference information over the total product life cycle, 2024. https:\/\/www.fda.gov\/media\/181509\/download. (Accessed April 30 2025)."},{"key":"10.1016\/j.lungcan.2026.109449_b0100","unstructured":"European Medicines Agency, Qualification Opinion of IMI PREFER, (2022)."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109449_b0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jval.2022.12.004","article-title":"A Roadmap for increasing the usefulness and impact of patient-preference studies in decision making in health: a good practices report of an ISPOR task force","volume":"26","author":"Bridges","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.lungcan.2026.109449_b0110","unstructured":"Food and Drug Administration, Guidance for industry: patient preference information \u2013 voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling, 2016. https:\/\/www.fda.gov\/media\/92593\/download. (Accessed April 30 2025)."},{"key":"10.1016\/j.lungcan.2026.109449_b0115","unstructured":"The PREFER consortium, PREFER recommendations - why, when and how to assess and use patient preferences in medical product decision-making, (2022)."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109449_b0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR good research practices for conjoint analysis task force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109449_b0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"32","author":"Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109449_b0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","article-title":"Sample size requirements for discrete-choice experiments in healthcare: a practical guide","volume":"8","author":"de Bekker-Grob","year":"2015","journal-title":"Patient"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109449_b0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","article-title":"Conjoint analysis applications in health - how are studies being designed and reported?: An update on current practice in the published literature between 2005 and 2008","volume":"3","author":"Marshall","year":"2010","journal-title":"Patient"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109449_b0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s11116-013-9451-z","article-title":"Sample size requirements for stated choice experiments","volume":"40","author":"Rose","year":"2013","journal-title":"Transportation"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109449_b0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","article-title":"Discrete choice experiments in health economics: past present and future","volume":"37","author":"Soekhai","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109449_b0150","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109449_b0155","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"31","key":"10.1016\/j.lungcan.2026.109449_b0160","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109449_b0165","doi-asserted-by":"crossref","unstructured":"C. Danes, W. Wan, J. Seo, M. Trapali, H. Clarke, J.A. Whitty, K.W. Culver, EP.12B.05 Drivers of Treatment Choice in ALK-Positive Metastatic Non-Small Cell Lung Cancer from Patients' and Caregivers' Perspectives, Journal of Thoracic Oncology 19(10, Supplement) (2024) S642.","DOI":"10.1016\/j.jtho.2024.09.1210"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109449_b0170","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","article-title":"A systematic review of discrete choice experiments in oncology treatments","volume":"14","author":"Collacott","year":"2021","journal-title":"The Patient - Patient-Centered Outcomes Research"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109449_b0175","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109449_b0180","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109449_b0185","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109449_b0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.025","article-title":"Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"139","author":"Nakagawa","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109449_b0195","unstructured":"Pfizer, LORBRENA\u00ae (lorlatinib) tablets, for oral use [prescribing information], (2021)."},{"key":"10.1016\/j.lungcan.2026.109449_b0200","unstructured":"Pfizer, XALKORI\u00ae (crizotinib) capsules, for oral use [package insert], (2022)."},{"key":"10.1016\/j.lungcan.2026.109449_b0205","unstructured":"Genentech Inc., ALECENSA\u00ae (alectinib) capsules, for oral use [package insert], (2015)."},{"key":"10.1016\/j.lungcan.2026.109449_b0210","unstructured":"Takeda Pharmaceutical Company Limited, ALUNBRIG\u00ae (brigatinib) tablets, for oral use [package insert], (Reference ID: 4612836) (2020)."},{"key":"10.1016\/j.lungcan.2026.109449_b0215","unstructured":"Food and Drug Administration, LORBRENA\u00ae (lorlatinib) tablets, for oral use 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210868s000lbl.pdf. (Accessed February 9 2024)."},{"key":"10.1016\/j.lungcan.2026.109449_b0220","unstructured":"Food and Drug Administration, ALECENSA\u00ae (alectinib) capsules, for oral use 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208434s010lbl.pdf. (Accessed February 9 2024)."},{"key":"10.1016\/j.lungcan.2026.109449_b0225","unstructured":"Food and Drug Administration, ALUNBRIG\u00ae (brigatinib) tablets, for oral use, 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208772s008lbl.pdf. (Accessed February 9 2024)."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109449_b0230","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jval.2025.04.062","article-title":"P46 probabilistic attribute presentation in discrete choice experiments (DCEs): a review of current practice","volume":"28","author":"Fernandez","year":"2025","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109449_b0235","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40273-025-01495-y","article-title":"The evolving landscape of discrete choice experiments in health economics: a systematic review","volume":"43","author":"Nouwens","year":"2025","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109449_b0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","article-title":"The internal validity of discrete choice experiment data: a testing tool for quantitative assessments","volume":"22","author":"Johnson","year":"2019","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109449_b0245","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/01441640902827623","article-title":"Constructing efficient stated choice experimental designs","volume":"29","author":"Rose","year":"2009","journal-title":"Transp. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109449_b0250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40271-020-00475-y","article-title":"Benefit-risk or risk-benefit trade-offs? Another look at attribute ordering effects in a pilot choice experiment","volume":"14","author":"Heidenreich","year":"2021","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109449_b0255","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00133443","article-title":"The structure of random utility models","volume":"8","author":"Manski","year":"1977","journal-title":"Theor. Decis."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109449_b0260","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109449_b0265","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/cncr.23968","article-title":"Cancer patient preferences for quality and length of life","volume":"113","author":"Meropol","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109449_b0270","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1200\/EDBK_280279","article-title":"Medical decision-making in oncology for patients lacking capacity","volume":"40","author":"Marron","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.lungcan.2026.109449_b0275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/PPA.S338840","article-title":"Patient and caregiver preferences for first-line treatments of metastatic non-small cell lung cancer: a discrete choice experiment","volume":"16","author":"Yong","year":"2022","journal-title":"Patient Prefer. Adherence"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109449_b0280","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40271-023-00625-y","article-title":"Taking the shortcut: simplifying heuristics in discrete choice experiments","volume":"16","author":"Veldwijk","year":"2023","journal-title":"Patient"},{"key":"10.1016\/j.lungcan.2026.109449_b0285","unstructured":"Catalogue of Bias Collaboration, J. Brassey, K.R. Mahtani, E.A. Spencer, C. Heneghan, Volunteer bias, 2017. http:\/\/www.catalogofbias.org\/biases\/volunteer-bias."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:44:54Z","timestamp":1781210694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"alternative-id":["S0169500226005106"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109449","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient and caregiver priorities of treatment characteristics influencing preferences for tyrosine kinase inhibitors in anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Pharmaceuticals America, Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109449"}}